COO & Chief Medical Officer of AspenBio Pharma Inc. (APPY, Financial) Robert Frederick Caspari buys 3,200 shares of APPY on 05/18/2009 at an average price of $1.57 a share.
ASPENBIO PHARMA INC. is an emerging bio-pharmaceutical company dedicated to the discovery development manufacture and marketing of novel proprietary products including those that enhance the reproductive efficiency of animals and that have large worldwide market potential. The company was originally formed to produce purified proteins for diagnostic applications and has become a leading supplier of human hormones to many of the nation's largest medical diagnostic companies and research institutions. The company has successfully leveraged this foundational science and technology expertise to rapidly develop an enviable late-stage pipeline of several novel reproduction hormone analogs for wide-ranging therapeutic use initially in bovine and equine species. AspenBio Pharma continues to make exciting progress in the development and testing of its two first-generation blood-based human diagnostic tests designed to rapidly help diagnose or rule out appendicitis in patients comp AspenBio Pharma Inc. has a market cap of $49.1 million; its shares were traded at around $1.5501 with and P/S ratio of 59.9.
Recent Trades of AspenBio Pharma Inc. by Directors and Officers:
ASPENBIO PHARMA INC. is an emerging bio-pharmaceutical company dedicated to the discovery development manufacture and marketing of novel proprietary products including those that enhance the reproductive efficiency of animals and that have large worldwide market potential. The company was originally formed to produce purified proteins for diagnostic applications and has become a leading supplier of human hormones to many of the nation's largest medical diagnostic companies and research institutions. The company has successfully leveraged this foundational science and technology expertise to rapidly develop an enviable late-stage pipeline of several novel reproduction hormone analogs for wide-ranging therapeutic use initially in bovine and equine species. AspenBio Pharma continues to make exciting progress in the development and testing of its two first-generation blood-based human diagnostic tests designed to rapidly help diagnose or rule out appendicitis in patients comp AspenBio Pharma Inc. has a market cap of $49.1 million; its shares were traded at around $1.5501 with and P/S ratio of 59.9.
Recent Trades of AspenBio Pharma Inc. by Directors and Officers:
- Buy: COO & Chief Medical Officer Robert Frederick Caspari bought 3,200 shares of APPY stock on 05/18/2009 at the average price of $1.57; the price of the stock has decreased by 1.27% since.
- Sell: Director Douglas I Hepler sold 5,000 shares of APPY stock on 05/06/2009 at the average price of $1.77; the price of the stock has decreased by 12.42% since.
- Sell: Director Douglas I Hepler sold 10,000 more shares of APPY stock on 04/29/2009 at the average price of $1.65; the price of the stock has decreased by 6.05% since.
- Sell: Director Douglas I Hepler sold 10,000 more shares of APPY stock on 03/30/2009 at the average price of $1.63; the price of the stock has decreased by 4.9% since.
- Sell: Director Douglas I Hepler sold 5,000 more shares of APPY stock on 01/05/2009 at the average price of $6.36; the price of the stock has decreased by 75.63% since.
